Compare FLO & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLO | AVLN |
|---|---|---|
| Founded | 1919 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2000 | 2026 |
| Metric | FLO | AVLN |
|---|---|---|
| Price | $5.83 | $25.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.40 | ★ $61.80 |
| AVG Volume (30 Days) | ★ 7.5M | 265.6K |
| Earning Date | 11-05-2026 | 11-25-2026 |
| Dividend Yield | ★ 8.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $5,256,479,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | ★ 3.00 | N/A |
| 52 Week Low | $5.40 | $24.14 |
| 52 Week High | $13.11 | $40.17 |
| Indicator | FLO | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 31.54 |
| Support Level | $5.40 | $24.90 |
| Resistance Level | $8.94 | $30.45 |
| Average True Range (ATR) | 0.20 | 1.84 |
| MACD | 0.07 | -0.31 |
| Stochastic Oscillator | 61.04 | 16.54 |
Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.